Pfizer: to present its latest data to ASH and SABCS
(CercleFinance.com) - Pfizer will present the latest advances in its growing hematology and breast cancer portfolios at the American Society of Hematology (ASH) Annual Meeting & Exposition (7-10 December) and the San Antonio Breast Cancer Symposium (SABCS, 10-13 December).
Data from more than 100 company-sponsored, investigator and collaborative research abstracts will be shared on the company's approved drugs and its growing portfolio of potential breakthroughs for patients with blood and breast cancers, as well as rare blood disorders.
Our strong presence at ASH and SABCS reinforces Pfizer's legacy of scientific innovation for people with blood disorders and breast cancer, Pfizer said.
We are pleased to share the latest updates on some of our leading approved medicines, including ADCETRIS, ELREXFIO and IBRANCE, which continue to generate compelling data as the foundation of care in their respective indications. We are also delighted to present new results in hemophilia and from our expanding portfolio of innovative next-generation therapies for blood and breast cancers, including new data on combination approaches in our key scientific modalities.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Data from more than 100 company-sponsored, investigator and collaborative research abstracts will be shared on the company's approved drugs and its growing portfolio of potential breakthroughs for patients with blood and breast cancers, as well as rare blood disorders.
Our strong presence at ASH and SABCS reinforces Pfizer's legacy of scientific innovation for people with blood disorders and breast cancer, Pfizer said.
We are pleased to share the latest updates on some of our leading approved medicines, including ADCETRIS, ELREXFIO and IBRANCE, which continue to generate compelling data as the foundation of care in their respective indications. We are also delighted to present new results in hemophilia and from our expanding portfolio of innovative next-generation therapies for blood and breast cancers, including new data on combination approaches in our key scientific modalities.
Copyright (c) 2024 CercleFinance.com. All rights reserved.